JP2003515560A - トロンボポイエチン模倣物 - Google Patents

トロンボポイエチン模倣物

Info

Publication number
JP2003515560A
JP2003515560A JP2001541505A JP2001541505A JP2003515560A JP 2003515560 A JP2003515560 A JP 2003515560A JP 2001541505 A JP2001541505 A JP 2001541505A JP 2001541505 A JP2001541505 A JP 2001541505A JP 2003515560 A JP2003515560 A JP 2003515560A
Authority
JP
Japan
Prior art keywords
hydroxy
naphtho
imidazole
imidazol
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001541505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515560A5 (enExample
Inventor
フアン・イ・ルエンゴ
ケビン・ジェイ・ダフィ
アラン・ティ・プライス
ジャン・リファ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2003515560A publication Critical patent/JP2003515560A/ja
Publication of JP2003515560A5 publication Critical patent/JP2003515560A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2001541505A 1999-12-06 2000-12-06 トロンボポイエチン模倣物 Pending JP2003515560A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16913099P 1999-12-06 1999-12-06
US60/169,130 1999-12-06
PCT/US2000/033432 WO2001039773A1 (en) 1999-12-06 2000-12-06 Thrombopoietin mimetics

Publications (2)

Publication Number Publication Date
JP2003515560A true JP2003515560A (ja) 2003-05-07
JP2003515560A5 JP2003515560A5 (enExample) 2008-01-31

Family

ID=22614367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001541505A Pending JP2003515560A (ja) 1999-12-06 2000-12-06 トロンボポイエチン模倣物

Country Status (7)

Country Link
EP (1) EP1244446B1 (enExample)
JP (1) JP2003515560A (enExample)
AT (1) ATE344031T1 (enExample)
AU (1) AU2079901A (enExample)
DE (1) DE60031714T2 (enExample)
ES (1) ES2275567T3 (enExample)
WO (1) WO2001039773A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528362A (ja) * 2003-08-14 2007-10-11 旭化成ファーマ株式会社 置換アリールアルカン酸誘導体及びその用途
JP2009504758A (ja) * 2005-08-15 2009-02-05 アイアールエム・リミテッド・ライアビリティ・カンパニー Tpo模倣剤としての化合物および組成物
US8436022B2 (en) 2006-07-11 2013-05-07 Daewoong Pharmaceutical Co., Ltd. Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851503B2 (en) 2002-08-14 2010-12-14 Nissan Chemical Industries, Ltd. Thrombopoetin receptor activator and process for producing the same
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
CN100513398C (zh) 2002-12-03 2009-07-15 Axys药物公司 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
JP4896518B2 (ja) * 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
US20060084682A1 (en) * 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
WO2006062240A1 (en) 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
KR101215207B1 (ko) 2004-12-14 2012-12-26 닛산 가가쿠 고교 가부시키 가이샤 아미드 화합물 및 트롬보포이에틴 리셉터 활성화제
EP1910338B1 (en) * 2005-07-14 2010-08-25 Irm, Llc Heterotetracyclic compounds as tpo mimetics
JP5071375B2 (ja) 2005-07-15 2012-11-14 日産化学工業株式会社 チオフェン化合物及びトロンボポエチンレセプター活性化剤
JP5104752B2 (ja) 2005-07-20 2012-12-19 日産化学工業株式会社 ピラゾール化合物及びトロンボポエチンレセプター活性化剤
US8026368B2 (en) 2005-11-07 2011-09-27 Nissan Chemical Industries, Ltd. Hydrazide compounds and thrombopoietin receptor activators
US8093251B2 (en) 2006-06-07 2012-01-10 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
NZ580662A (en) 2007-04-30 2012-01-12 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme used in manufacture of medicament for treatment of diabetes or lipid associated disorders
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
SI2807165T1 (sl) 2012-01-27 2019-08-30 Universite De Montreal Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic
CA2946446C (en) 2014-04-22 2020-11-03 Universite De Montreal Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
SG11201703407UA (en) 2014-10-31 2017-05-30 Nissan Chemical Ind Ltd Ligand-binding fiber and cell culture substrate using said fiber

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
DE4126612A1 (de) * 1990-08-14 1992-02-20 Ciba Geigy Ag Reaktivfarbstoffe, deren herstellung und verwendung
JPH06500316A (ja) * 1990-08-15 1994-01-13 ブリティッシュ バイオ―テクノロジー リミテッド 化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (enExample) *
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
DE4126612A1 (de) * 1990-08-14 1992-02-20 Ciba Geigy Ag Reaktivfarbstoffe, deren herstellung und verwendung
JPH06500316A (ja) * 1990-08-15 1994-01-13 ブリティッシュ バイオ―テクノロジー リミテッド 化合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528362A (ja) * 2003-08-14 2007-10-11 旭化成ファーマ株式会社 置換アリールアルカン酸誘導体及びその用途
JP2009504758A (ja) * 2005-08-15 2009-02-05 アイアールエム・リミテッド・ライアビリティ・カンパニー Tpo模倣剤としての化合物および組成物
US8436022B2 (en) 2006-07-11 2013-05-07 Daewoong Pharmaceutical Co., Ltd. Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same
US8940769B2 (en) 2006-07-11 2015-01-27 Daewoong Pharmaceutical Co., Ltd. Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
ES2275567T3 (es) 2007-06-16
EP1244446A4 (en) 2003-01-08
WO2001039773A1 (en) 2001-06-07
DE60031714T2 (de) 2007-09-06
AU2079901A (en) 2001-06-12
EP1244446A1 (en) 2002-10-02
ATE344031T1 (de) 2006-11-15
EP1244446B1 (en) 2006-11-02
DE60031714D1 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
JP3813875B2 (ja) トロンボポエチン摸倣物
EP1244446B1 (en) Thrombopoietin mimetics
JP4488663B2 (ja) トロンボポイエチン模倣物
ES2279769T3 (es) Mimeticos de trombopoyetina.
JP2006514951A (ja) トロンボポエチン模倣物
AU2001274938A1 (en) Thrombopoietin mimetics
JP2003513965A (ja) セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
US6858630B2 (en) Naphthimidazole derivatives and their use as thrombopoietin mimetics
EA019036B1 (ru) Способ получения 5-(2-аминопиримидин-4-ил)-2-арил-1н-пиррол-3-карбоксамидов
JP2004527541A (ja) トロンボポエチン模倣物
US20130078213A1 (en) Thrombopoietin mimetics
HK1117825B (en) Thrombopoietin mimetics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111101